Built to Scale Next-Gen Therapeutics
BioIP infrastructure
for the Regulated Therapeutics Economy
BioIP infrastructure
for the Regulated Therapeutics Economy
We develop and licenses BioIP—formulations, brand systems, and packaging—paired
with real assets that power the scale of compliant, next-gen therapeutic products.
We license formulations, brand IP,
and packaging systems to operators
in legal U.S. markets—while remaining
federally compliant and asset-light.
Backed by Strategy. Built for Scale.
Enabled by Strategic IP and deployable infrastructure.
From brand systems to physical production assets, our model is purpose-built to scale regulated therapeutics across legal U.S. markets—without cultivation, federal exposure, or capital-heavy overhead.
With a projected $95B+ addressable market by 2032 across functional therapeutics and psychoactive wellness, we deliver the infrastructure layer powering the next wave of health innovation.
Backed by Strategy. Built for Scale.
Enabled by Strategic IP and deployable infrastructure.
From brand systems to physical production assets, our model is purpose-built to scale regulated therapeutics across legal U.S. markets—without cultivation, federal exposure, or capital-heavy overhead.
With a projected $95B+ addressable market by 2032 across functional therapeutics and psychoactive wellness, we deliver the infrastructure layer powering the next wave of health innovation.
Nationally Trademarked Brands
Nationally Trademarked Brands
Nationally Trademarked Brands
U.S. States in Expansion Pipeline
U.S. States in Expansion Pipeline
U.S. States in Expansion Pipeline
Million (USD) in Active Sales Pipeline
Million (USD) in Active Sales Pipeline
Million (USD) in Active Sales Pipeline
Billion (USD) BioIP Infrastructure Market by 2032
Billion (USD) BioIP Infrastructure Market by 2032
Billion (USD) BioIP Infrastructure Market by 2032
Infrastructure that Unlocks Scale
The Infrastructure Gap
What Operators Are Up Against
No systems to scale legally or efficiently.
Fragmented state-by-state regulations
Limited access to capital and scalable systems
High-risk, compliance-heavy operating models
No unified platform for licensing, infrastructure, and commercialization
The Infrastructure Gap
What Operators Are Up Against
No systems to scale legally or efficiently.
Fragmented state-by-state regulations
Limited access to capital and scalable systems
High-risk, compliance-heavy operating models
No unified platform for licensing, infrastructure, and commercialization
The Infrastructure Gap
What Operators Are Up Against
No systems to scale legally or efficiently.
Fragmented state-by-state regulations
Limited access to capital and scalable systems
High-risk, compliance-heavy operating models
No unified platform for licensing, infrastructure, and commercialization
Federally compliant. Operator-ready. Built to scale across 24 U.S. states.
Our Model: BioIP Licensing + Infrastructure at Scale
We develop and license:
Fast-acting, formulation IP
Nationally trademarked brand systems
Sustainable, compliant packaging
Deployable production infrastructure
We license IP and infrastructure to operators in legal states—generating recurring royalties and lease income without cultivation, federal exposure, or capital-intensive operations.
Federally compliant. Operator-ready. Built to scale across 24 U.S. states.
Our Model: BioIP Licensing + Infrastructure at Scale
We develop and license:
Fast-acting, formulation IP
Nationally trademarked brand systems
Sustainable, compliant packaging
Deployable production infrastructure
We license IP and infrastructure to operators in legal states—generating recurring royalties and lease income without cultivation, federal exposure, or capital-intensive operations.
Federally compliant. Operator-ready. Built to scale across 24 U.S. states.
Our Model: BioIP Licensing + Infrastructure at Scale
We develop and license:
Fast-acting, formulation IP
Nationally trademarked brand systems
Sustainable, compliant packaging
Deployable production infrastructure
We license IP and infrastructure to operators in legal states—generating recurring royalties and lease income without cultivation, federal exposure, or capital-intensive operations.
The BioIP Infrastructure Model
How It Works
A model built for national scale.
License — We license BioIP (formulations, brand assets, packaging) to vetted, state-compliant manufacturers.
Equip — We lease deployable infrastructure: compliant equipment, real estate, and packaging systems.
Earn — We generate revenue through royalties and lease agreements—without plant-touching risk.
Consolidate — Upon federal legalization, we can acquire partner facilities to unify operations under one national entity.
The BioIP Infrastructure Model
How It Works
A model built for national scale.
License — We license BioIP (formulations, brand assets, packaging) to vetted, state-compliant manufacturers.
Equip — We lease deployable infrastructure: compliant equipment, real estate, and packaging systems.
Earn — We generate revenue through royalties and lease agreements—without plant-touching risk.
Consolidate — Upon federal legalization, we can acquire partner facilities to unify operations under one national entity.
The BioIP Infrastructure Model
How It Works
A model built for national scale.
License — We license BioIP (formulations, brand assets, packaging) to vetted, state-compliant manufacturers.
Equip — We lease deployable infrastructure: compliant equipment, real estate, and packaging systems.
Earn — We generate revenue through royalties and lease agreements—without plant-touching risk.
Consolidate — Upon federal legalization, we can acquire partner facilities to unify operations under one national entity.
Infrastructure Designed for Public Markets
Why BioIP Infrastructure Wins
Strategic Advantages:
Federally Compliant: No 280E tax exposure, no cultivation risk
High-Margin Revenue: Royalties + leases = capital-efficient scale
IPO Aligned: Infrastructure and legal structure built for public markets
Acquisition Ready: Exclusive M&A rights embedded in operator agreements
Infrastructure Designed for Public Markets
Why BioIP Infrastructure Wins
Strategic Advantages:
Federally Compliant: No 280E tax exposure, no cultivation risk
High-Margin Revenue: Royalties + leases = capital-efficient scale
IPO Aligned: Infrastructure and legal structure built for public markets
Acquisition Ready: Exclusive M&A rights embedded in operator agreements
Infrastructure Designed for Public Markets
Why BioIP Infrastructure Wins
Strategic Advantages:
Federally Compliant: No 280E tax exposure, no cultivation risk
High-Margin Revenue: Royalties + leases = capital-efficient scale
IPO Aligned: Infrastructure and legal structure built for public markets
Acquisition Ready: Exclusive M&A rights embedded in operator agreements
Our Edge
The therapeutic market is opening—but the infrastructure isn’t.
Unlike vertically integrated operators, we don’t grow, manufacture, or retail. Instead, we own the infrastructure layer: a capital-efficient, risk-mitigated platform that enables scale without exposure.
Our IP is protected, our assets are revenue-generating, and our agreements are built for consolidation the moment federal reform arrives.
The U.S. therapeutic landscape is shifting—fast. Cannabis and psychedelics are being legalized across 24+ states, yet most operators still face fragmented laws, heavy compliance burdens, and no infrastructure to scale. With a $95 Billion market emerging, the winners won’t just be product makers—they’ll be the platforms powering them.
No cultivation. No federal exposure. Just scale, royalties, and control.
Our Platform
A public-ready BioIP stack built to scale functional therapeutics.
We’ve built a BioIP infrastructure stack designed for this moment:
‣ Licensed formulations and brands
‣ Compliant packaging systems
‣ Deployable production infrastructure
Everything we offer is federally legal, public-market–ready, and structured for recurring revenue—through royalties, lease income, and exclusive partner rights.
We’ve built a BioIP infrastructure stack designed for this moment:
‣ Licensed formulations and brands
‣ Compliant packaging systems
‣ Deployable production infrastructure
Everything we offer is federally legal, public-market–ready, and structured for recurring revenue—through royalties, lease income, and exclusive partner rights.
We’ve built a BioIP infrastructure stack designed for this moment:
‣ Licensed formulations and brands
‣ Compliant packaging systems
‣ Deployable production infrastructure
Everything we offer is federally legal, public-market–ready, and structured for recurring revenue—through royalties, lease income, and exclusive partner rights.
Why Now
The U.S. market for next-generation therapeutics is expanding fast—driven by shifting state policies, consumer demand, and scientific momentum. But while products are gaining traction, the systems needed to commercialize them remain fragmented, costly, and inefficient.
As this $95B+ sector takes shape, the most valuable players won’t just create products—they’ll supply the infrastructure that powers them.
The U.S. market for next-generation therapeutics is expanding fast—driven by shifting state policies, consumer demand, and scientific momentum. But while products are gaining traction, the systems needed to commercialize them remain fragmented, costly, and inefficient.
As this $95B+ sector takes shape, the most valuable players won’t just create products—they’ll supply the infrastructure that powers them.
The therapeutic market is opening—but the infrastructure isn’t.
Everything you need to know
Do you manufacture or distribute any regulated substances?
What is BioIP and what exactly do you license?
How do you make money?
Where do you currently operate?
Are you exposed to federal regulatory risk (e.g., 280E)?
What’s your long-term strategy?
Everything you need to know
Do you manufacture or distribute any regulated substances?
What is BioIP and what exactly do you license?
How do you make money?
Where do you currently operate?
Are you exposed to federal regulatory risk (e.g., 280E)?
What’s your long-term strategy?
Everything you need to know
Do you manufacture or distribute any regulated substances?
What is BioIP and what exactly do you license?
How do you make money?
Where do you currently operate?
Are you exposed to federal regulatory risk (e.g., 280E)?
What’s your long-term strategy?
Let’s Build the Infrastructure for What’s Next
Whether you're an investor, operator, or strategic partner—join us in shaping the future of compliant, scalable therapeutics.
Let’s Build the Infrastructure for What’s Next
Whether you're an investor, operator, or strategic partner—join us in shaping the future of compliant, scalable therapeutics.
Let’s Build the Infrastructure
for What’s Next
Whether you're an investor, operator, or strategic partner—join us in shaping the future of compliant, scalable therapeutics.